S1R Stock Chart & Stats
€1.29
-€0.02(-1.32%)
At close: 4:00 PM EST
€1.29
-€0.02(-1.32%)
Day’s Range― - ―
52-Week Range€1.16 - €1.42
Previous CloseN/A
Volume0.00
Average Volume (3M)80.00
Market Cap
€7.39B
Enterprise Value€83.31K
Total Cash (Recent Filing)€40.98B
Total Debt (Recent Filing)€62.41B
Price to Earnings (P/E)10.6
Beta0.31
Next Earnings
Aug 28, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.55
Shares Outstanding919,072,700
10 Day Avg. Volume221
30 Day Avg. Volume80
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)0.50
Price to Sales (P/S)0.13
P/FCF Ratio9.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.16
Revenue Forecast (FY)€33.25B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelCombines large-scale distribution, manufacturing and related healthcare services to create multiple durable revenue streams. Distribution scale sustains volumes and customer relationships with hospitals and pharmacies, while manufacturing enables capture of higher-value product sales and vertical integration benefits over time.
Steady Revenue & EarningsConsistent top-line expansion and recurring positive earnings provide durable operational stability. Multi-year revenue growth (2021–2025) and improving net income reduce execution risk, supporting reinvestment in logistics, commercial reach and manufacturing scale that underpin medium-term competitiveness.
Positive Cash GenerationPersistent positive operating cash flow and a rebound in FCF enhance financial flexibility for capex, working-capital needs and shareholder returns. Reliable cash generation lowers dependence on external funding and supports steady investment in distribution infrastructure and manufacturing capabilities.
Bears Say
Thin Profit MarginsVery low net margins mean limited cushion against cost inflation, procurement pressure or reimbursement shifts. Margin structural thinness typical of distribution constrains retained earnings for growth, increases sensitivity to adverse mix shifts, and makes long-term profitability fragile without efficiency gains.
Moderate LeverageDebt at roughly two-thirds of equity indicates moderate leverage that can limit strategic flexibility. Interest obligations and refinancing risk may constrain ability to fund large-scale investments or M&A, and reduce the balance sheet buffer available during sector slowdowns or working-capital stress.
Working-capital IntensityModerate cash conversion and working-capital intensity point to potential volatility tied to receivables and inventory cycles. That dynamic can pressure liquidity during slower collections or inventory build, necessitating short-term financing and constraining margin recovery and reinvestment capacity over time.
Shanghai Pharmaceuticals Holding Co News
S1R FAQ
What was Shanghai Pharmaceuticals Holding Co Ltd Class H’s price range in the past 12 months?
Shanghai Pharmaceuticals Holding Co Ltd Class H lowest stock price was €1.16 and its highest was €1.42 in the past 12 months.
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap is €7.39B.
When is Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date is Aug 28, 2026 which is in 41 days.
How were Shanghai Pharmaceuticals Holding Co Ltd Class H’s earnings last quarter?
Shanghai Pharmaceuticals Holding Co Ltd Class H released its earnings results on Apr 29, 2026. The company reported €0.049 earnings per share for the quarter, beating the consensus estimate of €0.046 by €0.003.
Is Shanghai Pharmaceuticals Holding Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Pharmaceuticals Holding Co Ltd Class H’s price is currently Overvalued.
Does Shanghai Pharmaceuticals Holding Co Ltd Class H pay dividends?
Shanghai Pharmaceuticals Holding Co Ltd Class H does not currently pay dividends.
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate is 0.07.
How many shares outstanding does Shanghai Pharmaceuticals Holding Co Ltd Class H have?
Shanghai Pharmaceuticals Holding Co Ltd Class H has 919,072,700 shares outstanding.
What happened to Shanghai Pharmaceuticals Holding Co Ltd Class H’s price movement after its last earnings report?
Shanghai Pharmaceuticals Holding Co Ltd Class H reported an EPS of €0.049 in its last earnings report, beating expectations of €0.046. Following the earnings report the stock price went down -1.589%.
Which hedge fund is a major shareholder of Shanghai Pharmaceuticals Holding Co Ltd Class H?
Currently, no hedge funds are holding shares in DE:S1R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Pharmaceuticals Holding Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.50%
12-Months-Change
Fundamentals
Return on Equity
7.64%
Trailing 12-Months
Asset Growth
9.39%
Trailing 12-Months
Company Description
Shanghai Pharmaceuticals Holding Co Ltd Class H
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company based in Shanghai, People's Republic of China, maintains a robust presence across the pharmaceutical and healthcare industries. Its core activities involve the research, development, production, distribution, and retail of medical and wellness products. The company is strategically divided into Production, Distribution, Retail, and Other segments. Its comprehensive product portfolio includes Western and traditional Chinese medicines, health supplements, and medical devices, addressing a broad spectrum of therapeutic areas such as oncology, cardiovascular health, central nervous system disorders, general infections, immunology, digestive and metabolic conditions, and respiratory ailments, totaling approximately 700 distinct drug varieties. Beyond manufacturing, Shanghai Pharmaceuticals offers extensive pharmaceutical supply chain solutions, encompassing warehousing, logistics, and value-added services for manufacturers, hospitals, distributors, and retail pharmacies. The company also boasts a significant retail footprint, operating a network of approximately 2,000 retail pharmacies across 24 provinces, alongside an active online drug business. Furthermore, it provides various specialized services, including consulting, asset management, clinical trials, medical aid programs, physician and patient education, e-prescription management, and remote/cloud-based hospital services. Established in 1994, Shanghai Pharmaceuticals Holding Co., Ltd. operates as a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
Technical Analysis
China Health Group
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―
Charmacy Pharmaceutical Co., Ltd. Class H
―